Abstract:NALFD is becoming a global epidemic with severe complications, but few if any pharmacological therapies are available. Owing to its unique anatomy, microarchitecture, and cellular composition, the liver functions as an immune organ in addition to its roles in metabolism and detoxification. Innate immune signaling controls both inflammatory and metabolic profiles in the liver, and has potential to provide novel therapeutic targets in non-alcoholic steatohepatitis (NASH). Innate immune components mediate both canonical inflammation cascades and noncanonical metabolism-related pathways by modulating post-translational modifications or transcriptional coregulation, thus controlling NASH progression. Multi-omic analyses, cell signaling, and tissue-specific gene-editing technologies, combined with advances in disease models, will facilitate in-depth understanding of NAFLD and the discovery of new drugs. Non-alcoholic fatty liver disease (NAFLD) has become the most epidemic liver disease worldwide owing to rapid changes in lifestyle over the past few decades. This chronic condition intertwines with low-grade inflammation and metabolic disequilibrium, and potentiates the onset and progression of devastating hepatic and extrahepatic complications. In addition to an integral role in promoting host defense, recent studies also implicate innate immune signaling in a multitude of processes that control the progression of NAFLD. The focus of this review is to highlight emerging evidence regarding the role of innate immunity in NAFLD and the integration of different pathways that affect both inflammation and metabolism across the spectrum of this liver morbidity. Non-alcoholic fatty liver disease (NAFLD) has become the most epidemic liver disease worldwide owing to rapid changes in lifestyle over the past few decades. This chronic condition intertwines with low-grade inflammation and metabolic disequilibrium, and potentiates the onset and progression of devastating hepatic and extrahepatic complications. In addition to an integral role in promoting host defense, recent studies also implicate innate immune signaling in a multitude of processes that control the progression of NAFLD. The focus of this review is to highlight emerging evidence regarding the role of innate immunity in NAFLD and the integration of different pathways that affect both inflammation and metabolism across the spectrum of this liver morbidity.

Comprehensive Understanding of Immune Cells in the Pathogenesis of Non-alcoholic Fatty Liver

Immune cell-mediated features of non-alcoholic steatohepatitis

Immunomodulation in non-alcoholic fatty liver disease: exploring mechanisms and applications

Role of Innate Immune Signaling in Non-Alcoholic Fatty Liver Disease

Insights into the Epidemiology, Pathogenesis, and Therapeutics of Nonalcoholic Fatty Liver Diseases

Immune-related pathogenesis and therapeutic strategies of nonalcoholic steatohepatitis

Shedding light on non-alcoholic fatty liver disease: Pathogenesis, molecular mechanisms, models, and emerging therapeutics

Recent Progress of Proteomics in Nonalcoholic Fatty Liver Disease*

Role of Innate Immune Response in Non-Alcoholic Fatty Liver Disease: Metabolic Complications and Therapeutic Tools

The Role of Innate Immune Cells in Nonalcoholic Fatty Liver Disease

Immune system dysregulation in the pathogenesis of non-alcoholic steatohepatitis: unveiling the critical role of T and B lymphocytes

Immune cells and their derived microRNA-enriched extracellular vesicles in nonalcoholic fatty liver diseases: Novel therapeutic targets

Recent evaluation about inflammatory mechanisms in nonalcoholic fatty liver disease

Emerging targets and potential therapeutic agents in non-alcoholic fatty liver disease treatment

Pathogenetic Pathways in Nonalcoholic Fatty Liver Disease

Immune Imbalances in Non-Alcoholic Fatty Liver Disease: From General Biomarkers and Neutrophils to Interleukin-17 Axis Activation and New Therapeutic Targets

Emerging Molecular Targets for Treatment of Nonalcoholic Fatty Liver Disease

Role of hepatic lipid species in the progression of nonalcoholic fatty liver disease

Innate Immune System in the Pathogenesis of Non-Alcoholic Fatty Liver Disease

The role of immune cells in metabolism-related liver inflammation and development of non-alcoholic steatohepatitis (NASH)

Innate immunity and nonalcoholic fatty liver disease